The stock of MaxCyte Inc (MXCT) has seen a -11.73% decrease in the past week, with a -19.06% drop in the past month, and a -47.30% decrease in the past quarter. The volatility ratio for the week is 8.37%, and the volatility levels for the past 30 days are at 6.52% for MXCT. The simple moving average for the past 20 days is -18.11% for MXCT’s stock, with a -42.29% simple moving average for the past 200 days.
Is It Worth Investing in MaxCyte Inc (NASDAQ: MXCT) Right Now?
Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MXCT is 97.96M and currently, short sellers hold a 3.61% of that float. On May 15, 2025, MXCT’s average trading volume was 735.09K shares.
MXCT) stock’s latest price update
MaxCyte Inc (NASDAQ: MXCT)’s stock price has plunge by -2.50relation to previous closing price of 2.20. Nevertheless, the company has seen a -11.73% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-10 that MaxCyte, Inc. (NASDAQ:MXCT ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Eric Abdel – IR Maher Masoud – President and CEO Doug Swirsky – CFO Conference Call Participants Matt Larew – William Blair Julie Simmonds – Panmure Liberum Mark Massaro – BTIG Chad Wiatrowski – TD Cowen Dan Arias – Stifel Operator Good day and thank you for standing by. Welcome to the MaxCyte First Quarter Earnings Conference Call.
Analysts’ Opinion of MXCT
Many brokerage firms have already submitted their reports for MXCT stocks, with Craig Hallum repeating the rating for MXCT by listing it as a “Buy.” The predicted price for MXCT in the upcoming period, according to Craig Hallum is $7 based on the research report published on November 29, 2023 of the previous year 2023.
MXCT Trading at -23.17% from the 50-Day Moving Average
After a stumble in the market that brought MXCT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.22% of loss for the given period.
Volatility was left at 6.52%, however, over the last 30 days, the volatility rate increased by 8.37%, as shares sank -16.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.55% lower at present.
During the last 5 trading sessions, MXCT fell by -11.93%, which changed the moving average for the period of 200-days by -53.78% in comparison to the 20-day moving average, which settled at $2.62. In addition, MaxCyte Inc saw -48.44% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MXCT starting from Soleymannezhad Ali, who sale 1,211 shares at the price of $3.18 back on Mar 18 ’25. After this action, Soleymannezhad Ali now owns 59,439 shares of MaxCyte Inc, valued at $3,850 using the latest closing price.
Sandoval David I., the GENERAL COUNSEL of MaxCyte Inc, sale 353 shares at $3.18 during a trade that took place back on Mar 18 ’25, which means that Sandoval David I. is holding 64,219 shares at $1,122 based on the most recent closing price.
Stock Fundamentals for MXCT
Current profitability levels for the company are sitting at:
- -1.33 for the present operating margin
- 0.78 for the gross margin
The net margin for MaxCyte Inc stands at -1.11. The total capital return value is set at -0.23. Equity return is now at value -19.63, with -17.13 for asset returns.
Based on MaxCyte Inc (MXCT), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -1.67.
Currently, EBITDA for the company is -46.41 million with net debt to EBITDA at 0.1. When we switch over and look at the enterprise to sales, we see a ratio of 5.9. The receivables turnover for the company is 6.82for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.23.
Conclusion
To wrap up, the performance of MaxCyte Inc (MXCT) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
